DOCSLIB.ORG

Breast-Oncology Clinical Trials June 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Breast-Oncology Clinical Trials June 2021 Breast-Oncology Clinical Trials June 2021 Neoadjuvant PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status UCI 14-67: A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Pathologically proven invasive breast cancer HER-2 monoclonal antibody Mehta Ashley Chanthapadith Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Tumor size is clinically at least 1 cm in greatest diameter (palpable Open to Accrual VEGF monoclonal antibody Neoadjuvant Setting or by imaging) and/or with involved lymph node Adjuvant PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Patients must have undergone immediate reconstruction at the Alliance A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy fractionated external radiation Kuo Ashley Chanthapadith time of mastectomy or be planning to undergo reconstruction Open to Accrual Radiation with Breast Reconstruction therapy within 8 months after radiation A011801: The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Patients must have HER2+ breast cancer with residual disease Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Antibody drug conjugate + kinase Parajuli Ashley Chanthapadith after NACT Open to Accrual Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and inhibitor No prior treatment w/ TDM-1 Placebo Compared with T-DM1 and Tucatinib Post-menopausal female patients UCI 18-79: A Phase II Clinical Trial on Neo-Adjuvant Abemaciclib with Fulvestrant in Histologically confirmed ER+ Breast Cancer Patients with ER/PR + HER-2 Negative Breast Cancer who Developed Localized CKD Inhibitor + Neoadjuvant Patients must have localized recurrence while on adjuvant Parajuli Ashley Chanthapadith Open to Accrual Recurrence While on Adjuvant Endocrine Therapy with Molecular Evidence of Endocrine Therapy endocrine therapy Endocrine Resistance Patients must not have inflammatory breast cancer No prior treatment with any CDK 4/6 inhibitor and/or Fulvestrant Metastatic PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Locally advanced unresectable or metastatic ER+, HER2- breast UCI 20-60 A Phase Ia/Ib Study of LY3484356 Administered as Monotherapy and in cancer or endometrial cancer. Up to 3 lines of treatment in Parajuli Ashley Chanthapadith Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or non-covalent oral SERD Open to Accrual advanced/metastatic setting and progression while on endocrine Metastatic Breast Cancer and Other Select Non-Breast Cancers therapy. Patients must have history of prior treatment with a taxane and resistance to antibody-mediated trastuzumab in any setting, separately or in combination. Prior UCI 19-66: Randomized, Double-Blind, Phase III Study of Tucatinib or Placebo in inhibition using tyrosine kinase pertuzumab therapy is allowed, but not required. Parajuli Ashley Chanthapadith Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Open to Accrual inhibitor and antibody-based No prior treatment with tucatinib, lapatinib, neratinib, afatinib, Locally-Advanced or Metastatic HER2+ Breast Cancer therapy trastuzumab deruxtecan (DS-8201a), or any other investigational anti-HER2, anti-EGFR, or HER2 TKI agent or T-DM1. Histologically confirmed adenocarcinoma of the breast with locally NRG-BR004: A Randomized, Double-Blind, Phase III Trial of recurrent, unresectable disease or metastatic disease including: de PD-L1 antibody + HER2 Parajuli Ashley Chanthapadith Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive novo metastatic disease without prior history of HER2-positive BC Suspended monoclonal antibody Metastatic Breast Cancer or locally recurrent or metastatic disease following prior therapy for early BC Contact Info: A. Chanthapadith x509-2925/A.Serwanska x456-8279/ O. Quines x456-6244/E. Matsuda x509-2710/ C. Colmenares x509-2172/K. Ghio x456-6285/M.Tharani x509-2643/K. Buttigieg x456-7429/J. Balangue x509-2948 Page 1 July 2021 Breast-Oncology Clinical Trials June 2021 Metastatic HR+/HER2- breast cancer with progression on an AI UCI 19-88: A Phase III Double-Blind Randomised Study Assessing the Efficacy and Safety of AKT inhibitor + selective estrogen No more than 1 line of chemotherapy or more than 2 lines of Coluzzi Ashley Chanthapadith Capivasertib + Fulvestrant versus Placebo + Fulvestrant as Treatment for Locally Advanced Open to Accrual down-regulator endocrine therapy in the metastatic setting (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growt No prior treatment with Fulvestrant or AKT/PI3K/mTOR inhibitors IgG1 monoclonal antbody binding UCI 17-79: Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab for first- to LIV-1 and linker in lysosomes Metastatic or locally-advanced triple-negative breast cancer Parajuli Ashley Chanthapadith line treatment of patients with unresectable locally advanced or metastatic triple- Open to Accrual releasing MMAE which prevents Have not previously received therapy for the treatment negative breast cancer cell division. Histologically confirmed metastatic disease to the brain from any solid tumor. If progression occurred for the following tx in the CDK inhibitor + PI3K inhibitor + Bota Mehir Tharani Alliance A071701: Genetic Testing in Guiding Treatment for Patients with Brain Metastases metastatic setting: for HER2-positive breast cancer received prior Open to Accrual NTRK/ROS1 inhibitor HER-2 directed therapy; for TNBC, at least one chemotherapy in metastatic setting HER2-, metastatic breast cancer ETCTN 10302: Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Bone-targeted alpha particle If HR+, disease should have progressed on at least one line of Parajuli Ashley Chanthapadith Open to Accrual Patients with Bone Metastatic Breast Cancer emitting radiopharmaceutical hormone therapy and a CDK 4/6 inhibitor in metastatic setting No prior therapy w/ radionuclides HR+/HER2- metastatic breast cancer No more than one chemotherapy line in metastatic setting ETCTN 10287: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination For patients enrolling on Phase 2 portion of the study: Parajuli Ashley Chanthapadith with Copanlisib (FAC) versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Pan-class I PI3K inhibitor - must have resistance to endocrine therapy in metastatic setting Suspended Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA) -no prior treatment w/ CDK 4/6 inhibitor, Fulvestrant, or PI3K inhibitor in metastatic setting -no brain metastasis Metastatic triple negative breast cancer ETCTN 10146: Randomized Phase II Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + IgG monoclonal antibody + IgG2 Must be PD-L1 negative and have not received any prior therapies Parajuli Ashley Chanthapadith Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) + monoclonal antibody + synthetic for metastatic TNBC Open to Accrual Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer neoantigen targeting vaccine Must be considered a candidate for first line carboplatin + gemcitabine Histologic or cytologic diagnosis of a malignant soild tumor Subjects enrolled in Part 2a (monotherapy, dose expansion) must have SCLC with tumors that express B7H3 above a UCI 18-43: A Phase 1 First in Human Study Evaluating Safety and Efficacy of ABBV-155 given threshold per central laboratory testing; Parajuli Ashley Chanthapadith Monotherapy and Combined with Docetaxel in Adult Patients with Relapsed and Refractory Antibody drug conjugate Subjects enrolled to Part 2b (combination Open to Accrual Solid Tumors therapy, dose expansion) must have either NSCLC or HR+/HER2- breast cancer with tumors that express B7H3 above a given threshold per central laboratory testing and must have failed CDK 4/6 therapy Solid Tumors/Basket Trials PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Patients must have a metastatic solid tumor with MAPK-pathway alterations (excluding BRAF V600x) and no avaialble SOC therapies UCI 20-179: A Phase I/IB First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Rezazadeh TBD SHP2 inhibitor Patients with tumors harboring known activating mutations in Pending Activation Known as IACS-15509) in Patients with Advanced Solid Tumors BRAF V600X or SHP2 will be excluded Patients must not have previously received a SHP2 inhibitor Contact Info: A. Chanthapadith x509-2925/A.Serwanska x456-8279/ O. Quines x456-6244/E. Matsuda x509-2710/ C. Colmenares x509-2172/K. Ghio x456-6285/M.Tharani x509-2643/K. Buttigieg x456-7429/J. Balangue x509-2948 Page 2 July 2021 Breast-Oncology Clinical Trials June 2021 Solid Tumors/Basket Trials Have a solid tumor, pancreatic cancer, NSCLC with any activating mutation(s) in the MAPK pathway, and have not previously received a MAPK inhibitor Have melanoma or NSCLC with a BRAF V600 mutation and have UCI 21-55: A Phase Ib/II, Open-Label, Multi-Center Study of ERAS-007 ERK Inhibitor in Ou Oliver Quines ERK inhibitor not previously received a BRAF inhibitor Pending Activation Patients with Advanced or Metastatic Solid Tumors Have NSCLC with a KRAS G12C alteration, and not previously received a KRAS G12C inhibitor For all cohorts, there must be no available standard systemic therapy available and no prior treatment with an ERK inhibitor Advanced solid tumors that have failed, are intolerant to, or are UCI
Load more

Recommended publications
  • Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
    Published OnlineFirst September 23, 2016; DOI: 10.1158/1078-0432.CCR-16-0620 Biology of Human Tumors Clinical Cancer Research Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin- Dependent Kinase 2 and AKT Inhibition George Au-Yeung1,2, Franziska Lang1, Walid J. Azar1, Chris Mitchell1, Kate E. Jarman3, Kurt Lackovic3,4, Diar Aziz5, Carleen Cullinane1,6, Richard B. Pearson1,2,7, Linda Mileshkin2,8, Danny Rischin2,8, Alison M. Karst9, Ronny Drapkin10, Dariush Etemadmoghadam1,2,5, and David D.L. Bowtell1,2,7,11 Abstract Purpose: Cyclin E1 (CCNE1) amplification is associated with Results: We validate CDK2 as a therapeutic target by demon- primary treatment resistance and poor outcome in high-grade strating selective sensitivity to gene suppression. However, we found serous ovarian cancer (HGSC). Here, we explore approaches to that dinaciclib did not trigger amplicon-dependent sensitivity in a target CCNE1-amplified cancers and potential strategies to over- panel of HGSC cell lines. A high-throughput compound screen come resistance to targeted agents. identified synergistic combinations in CCNE1-amplified HGSC, Experimental Design: To examine dependency on CDK2 in including dinaciclib and AKT inhibitors. Analysis of genomic data CCNE1-amplified HGSC, we utilized siRNA and conditional from TCGA demonstrated coamplification of CCNE1 and AKT2. shRNA gene suppression, and chemical inhibition using dina- Overexpression of Cyclin E1 and AKT isoforms, in addition to ciclib, a small-molecule CDK2 inhibitor. High-throughput mutant TP53, imparted malignant characteristics in untransformed compound screening was used to identify selective synergistic fallopian tube secretory cells, the dominant site of origin of HGSC.
    [Show full text]
  • The CDK4/6 Inhibitor LY2835219 Has Potent Activity in Combination with Mtor Inhibitor in Head and Neck Squamous Cell Carcinoma
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 12 The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma Bo Mi Ku1,*, Seong Yoon Yi3,*, Jiae Koh1, Yeon-Hee Bae1, Jong-Mu Sun2, Se-hoon Lee2, Jin Seok Ahn2, Keunchil Park2, Myung-Ju Ahn2 1 Samsung Biomedical Research Institute, Seoul, Korea 2 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 3 Division of Hematology-Oncology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Gyeonggi-do, Korea *These authors contributed equally to this work Correspondence to: Myung-Ju Ahn, e-mail: [email protected] Keywords: head and neck cancer, CDK4/6 inhibitor, mTOR, cell cycle, targeted therapy Received: September 15, 2015 Accepted: January 23, 2016 Published: February 21, 2016 ABSTRACT Deletion of CDKN2A (p16) or amplification ofCCND1 (cyclin D1) occurs commonly in head and neck squamous cell carcinoma (HNSCC) and induces sustained cyclin- dependent kinase (CDK) 4/6 activation. Here, we report the antiproliferative activity of LY2835219, a selective CDK4/6 inhibitor through inhibition of CDK4/6-dependent Ser780 phosphorylation in retinoblastoma (RB) and induction of cell cycle arrest in HNSCC cells. In addition, we demonstrated the antitumor effects of HNSCC xenografts to LY2835219 in vivo. Given the limited effect in HNSCC as a single-agent treatment with LY2835219, a combinational strategy is required to enhance antitumor activity. At the molecular level, we found that LY2835219 inhibited activation of AKT and ERK, but not mTOR. The combination of LY2835219 with mTOR inhibitor was found to be more effective than either drug alone in vitro and in vivo.
    [Show full text]
  • Identification of Candidate Repurposable Drugs to Combat COVID-19 Using a Signature-Based Approach
    www.nature.com/scientificreports OPEN Identifcation of candidate repurposable drugs to combat COVID‑19 using a signature‑based approach Sinead M. O’Donovan1,10, Ali Imami1,10, Hunter Eby1, Nicholas D. Henkel1, Justin Fortune Creeden1, Sophie Asah1, Xiaolu Zhang1, Xiaojun Wu1, Rawan Alnafsah1, R. Travis Taylor2, James Reigle3,4, Alexander Thorman6, Behrouz Shamsaei4, Jarek Meller4,5,6,7,8 & Robert E. McCullumsmith1,9* The COVID‑19 pandemic caused by the novel SARS‑CoV‑2 is more contagious than other coronaviruses and has higher rates of mortality than infuenza. Identifcation of efective therapeutics is a crucial tool to treat those infected with SARS‑CoV‑2 and limit the spread of this novel disease globally. We deployed a bioinformatics workfow to identify candidate drugs for the treatment of COVID‑19. Using an “omics” repository, the Library of Integrated Network‑Based Cellular Signatures (LINCS), we simultaneously probed transcriptomic signatures of putative COVID‑19 drugs and publicly available SARS‑CoV‑2 infected cell lines to identify novel therapeutics. We identifed a shortlist of 20 candidate drugs: 8 are already under trial for the treatment of COVID‑19, the remaining 12 have antiviral properties and 6 have antiviral efcacy against coronaviruses specifcally, in vitro. All candidate drugs are either FDA approved or are under investigation. Our candidate drug fndings are discordant with (i.e., reverse) SARS‑CoV‑2 transcriptome signatures generated in vitro, and a subset are also identifed in transcriptome signatures generated from COVID‑19 patient samples, like the MEK inhibitor selumetinib. Overall, our fndings provide additional support for drugs that are already being explored as therapeutic agents for the treatment of COVID‑19 and identify promising novel targets that are worthy of further investigation.
    [Show full text]
  • A Novel CDK9 Inhibitor Increases the Efficacy of Venetoclax (ABT-199) in Multiple Models of Hematologic Malignancies
    Leukemia (2020) 34:1646–1657 https://doi.org/10.1038/s41375-019-0652-0 ARTICLE Molecular targets for therapy A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies 1 1 2,3 4 1 5 6 Darren C. Phillips ● Sha Jin ● Gareth P. Gregory ● Qi Zhang ● John Xue ● Xiaoxian Zhao ● Jun Chen ● 1 1 1 1 1 1 Yunsong Tong ● Haichao Zhang ● Morey Smith ● Stephen K. Tahir ● Rick F. Clark ● Thomas D. Penning ● 2,7 3 5 1 4 2,7 Jennifer R. Devlin ● Jake Shortt ● Eric D. Hsi ● Daniel H. Albert ● Marina Konopleva ● Ricky W. Johnstone ● 8 1 Joel D. Leverson ● Andrew J. Souers Received: 27 November 2018 / Revised: 18 October 2019 / Accepted: 13 November 2019 / Published online: 11 December 2019 © The Author(s) 2019 Abstract MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax. The expression of MCL-1 is maintained via P-TEFb-mediated transcription, where the kinase CDK9 is a critical component. Consequently, we developed a series of potent small-molecule inhibitors of CDK9, exemplified by the orally active A-1592668, with CDK selectivity profiles 1234567890();,: 1234567890();,: that are distinct from related molecules that have been extensively studied clinically. Short-term treatment with A-1592668 rapidly downregulates RNA pol-II (Ser 2) phosphorylation resulting in the loss of MCL-1 protein and apoptosis in MCL-1- dependent hematologic tumor cell lines. This cell death could be attenuated by either inhibiting caspases or overexpressing BCL-2 protein.
    [Show full text]
  • Cyclacel's CYC065 CDK Inhibitor Demonstrates Synergy With
    Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia April 17, 2018 Suppression of both BCl-2 and Mcl-1 anti-apoptotic proteins is a novel strategy in CLL BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the presentation by investigators led by William Plunkett, PhD, Professor and Deputy Chair, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, of preclinical data demonstrating strong synergy between Cyclacel’s CDK2/9 inhibitor, CYC065, and the Bcl-2 inhibitor, venetoclax (ABT-199, AbbVie) in chronic lymphocytic leukemia (CLL) samples obtained from patients. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois. “The MD Anderson data show that the combination of CYC065 and venetoclax is strongly synergistic in primary CLL cells from patients, including those with 17p deletions. In addition, the combination was active in two CLL samples which were resistant to either agent alone. These findings support the hypothesis that dual targeting of the Mcl-1- and Bcl-2-dependent mechanisms could induce synergistic cell death by apoptosis,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. “Last weekend during the same AACR conference, we reported that CYC065 durably suppresses Mcl-1, a member of the Bcl-2 family of survival proteins, in patients with advanced solid tumors1.
    [Show full text]
  • Pharmacologic Properties of AG-012986, a Pan-Cyclin- Dependent Kinase Inhibitor with Antitumor Efficacy
    818 Pharmacologic properties of AG-012986, a pan-cyclin- dependent kinase inhibitor with antitumor efficacy Cathy Zhang,1 Karen Lundgren,1 Zhengming Yan,1 optimization of AG-012986 provided guidance for select- Maria E. Arango,1 Sharon Price,1 Andrea Huber,1 ing a treatment schedule to achieve the best antitumor Joseph Higgins,1 Gabriel Troche,1 efficacy while minimizing the risk of adverse side effects. Judith Skaptason,2 Tatiana Koudriakova,2 [Mol Cancer Ther 2008;7(4):818–28] Jim Nonomiya,4 Michelle Yang,5 1 1 1 Patrick O’Connor, Steve Bender, Gerrit Los, Introduction Cristina Lewis,4 and Bart Jessen3 Cyclin-dependent kinases (CDK) and their regulatory Departments of 1Cancer Biology, 2Pharmacokinetics, Dynamics cyclin partners play critical roles in cell cycle control and and Metabolism, 3Drug Safety Research and Development, the regulation of cell transcription. Progression through 4 5 Biochemical Pharmacology, and Medicinal Chemistry, the different stages of cell cycle is governed by the Pfizer Global Research and Development, La Jolla, California activities of the CDK1, CDK2, CDK4, CDK6, and possibly CDK3. CDK4/cyclin D, CDK6/cyclin D, and CDK2/cyclin E Abstract phosphorylate the retinoblastoma (Rb) protein at multiple AG-012986 is a multitargeted cyclin-dependent kinase sites, which results in activation of the E2F family of (CDK) inhibitor active against CDK1, CDK2, CDK4/6, transcription factors and serves as a trigger for cells to CDK5, and CDK9, with selectivity over a diverse panel of advance beyond the G1 checkpoint into S phase (1–3). non-CDK kinases. Here, we report the potent antitumor During S phase, CDK2/cyclin A phosphorylates several efficacies of AG-012986 against multiple tumor lines proteins, including E2F, to regulate progression through in vitro and in vivo.
    [Show full text]
  • Anticancer and Radiosensitizing Effects of the Cyclin-Dependent Kinase Inhibitors, AT7519 and SNS‑032, on Cervical Cancer
    INTERNATIONAL JOURNAL OF ONCOLOGY 53: 703-712, 2018 Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical cancer MI AE KANG1*, WONWOO KIM2*, HYE-RAM JO1,3, YOUNG-JOO SHIN4, MOON-HONG KIM5 and JAE-HOON JEONG1,3 1Division of Applied Radiation Bioscience, and 2Radiation Non-Clinic Center, Korea Institute of Radiological and Medical Science, Seoul 01812; 3Radiological and Medico-Oncological Sciences, Korea University of Science and Technology, Daejeon 34113; 4Department of Radiation Oncology, Inje University Sanggye Paik Hospital, Seoul 01757; 5Department of Obstetrics and Gynecology, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea Received January 30, 2018; Accepted May 17, 2018 DOI: 10.3892/ijo.2018.4424 Abstract. Cyclin-dependent kinases (CDK) are considered the utilization of AT7519 and SNS-032 as part of an adjuvant to be potential targets of anticancer drugs that can interrupt treatment may help control cervical cancer progression. the uncontrolled division of cancer cells. In this study, we selected two selective CDK inhibitors, AT7519 and SNS-032, Introduction from current clinical trials and examined their anticancer and radiosensitizing effects in a cervical cancer model. SNS-032 Cyclin-dependent kinases (CDKs) are present in all known was found to be more potent than AT7519, with a lower half eukaryotes, and their regulatory functions during the cell cycle maximal inhibitory concentration (IC50) value. Both AT7519 are evolutionarily conserved. Cyclin-CDK complexes phos- and SNS-032 induced the apoptosis, premature senescence and phorylate specific substrates, according to the requirements cytostasis of cervical cancer cells, which led to the attenuation of a particular cell cycle phase.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC † 5) F. Cardoso, S. Paluch-Shimon, E. Senkus, G. Curigliano, M.S. Aapro, F. André, C.H. Barrios, J. Bergh, G.S. Bhattacharyya, L. Biganzoli, F. Boyle, M.-J. Cardoso, L.A. Carey, J. Cortés, N.S. El Saghir, M. Elzayat, A. Eniu, L. Fallowfield, P.A. Francis, K. Gelmon, J. Gligorov, R. Haidinger, N. Harbeck, X. Hu, B. Kaufman, R. Kaur, B.E. Kiely, S.-B. Kim, N.U. Lin, S.A. Mertz, S. Neciosup, B.V. Offersen, S. Ohno, O. Pagani, A. Prat, F. Penault-Llorca, H.S. Rugo, G.W. Sledge, C. Thomssen, D.A. Vorobiof, T. Wiseman, B. Xu, L. Norton, A. Costa, E.P. Winer PII: S0923-7534(20)42460-3 DOI: https://doi.org/10.1016/j.annonc.2020.09.010 Reference: ANNONC 337 To appear in: Annals of Oncology Received Date: 21 August 2020 Revised Date: 15 September 2020 Accepted Date: 16 September 2020 Please cite this article as: Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP, 5th ESO-ESMO international consensus guidelines for advanced breast † cancer (ABC 5) , Annals of Oncology (2020), doi: https://doi.org/10.1016/j.annonc.2020.09.010.
    [Show full text]
  • As of May 1, 2018
    Pfizer Pipeline As of May 1, 2018 Disclaimer ● As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 1, 2018. ● Visit Pfizer.com/pipeline, Pfizer’s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2 Table of Contents Pfizer Pipeline Snapshot 4 Inflammation and Immunology 5 Metabolic Disease and Cardiovascular Risks 6 Oncology 7-9 Rare Diseases 10 Vaccines 11 Biosimilars and Other Areas of Focus 12 Projects Discontinued Since Last Update 13 Backup: Regulatory Designation Definitions 14-15 3 * A portion of the increase in the number of projects in Phase 1 and Phase 2 Pfizer Pipeline Snapshot between the January 30, 2018 and May 1, 2018 updates is attributable to a change in project counting Pfizer Pipeline 10 programs advanced practices. Multiple Snapshot as of indications previously or are new combined and reflected as a Discovery May 1, 2018 single project are now being Projects counted separately. This change has been Phase 1 * Phase 2 * Phase 3 Registration Total implemented to increase 34 22 28 12 96 transparency and provide a more comprehensive view of our early and mid-stage portfolio.
    [Show full text]
  • Cyclin-Dependent Kinase Inhibitors in Brain Cancer: Current State and Future Directions
    Juric et al. Cancer Drug Resist 2020;3:48-62 Cancer DOI: 10.20517/cdr.2019.105 Drug Resistance Review Open Access Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions Viktorija Juric, Brona Murphy Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin D02, Ireland. Correspondence to: Dr. Brona Murphy, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, 39A York Street, Dublin D02, Ireland. E-mail: [email protected] How to cite this article: Juric V, Murphy B. Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. Cancer Drug Resist 2020;3:48-62. http://dx.doi.org/10.20517/cdr.2019.105 Received: 5 Nov 2019 First Decision: 4 Dec 2019 Revised: 11 Dec 2019 Accepted: 20 Dec 2019 Published: 19 Mar 2020 Science Editor: Lee M. Graves Copy Editor: Jing-Wen Zhang Production Editor: Jing Yu Abstract Cyclin-dependent kinases (CDKs) are important regulatory enzymes in the normal physiological processes that drive cell-cycle transitions and regulate transcription. Virtually all cancers harbour genomic alterations that lead to the constitutive activation of CDKs, resulting in the proliferation of cancer cells. CDK inhibitors (CKIs) are currently in clinical use for the treatment of breast cancer, combined with endocrine therapy. In this review, we describe the potential of CKIs for the treatment of cancer with specific focus on glioblastoma (GBM), the most common and aggressive primary brain tumour in adults. Despite intense effort to combat GBM with surgery, radiation and temozolomide chemotherapy, the median survival for patients is 15 months and the majority of patients experience disease recurrence within 6-8 months of treatment onset.
    [Show full text]
  • Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
    International Journal of Molecular Sciences Review Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action Paweł Łukasik 1, Irena Baranowska-Bosiacka 2, Katarzyna Kulczycka 3 and Izabela Gutowska 1,* 1 Department of Medical Chemistry, Pomeranian Medical University in Szczecin, Powstancow Wlkp. 72 Av., 70-111 Szczecin, Poland; [email protected] 2 Department of Biochemistry, Pomeranian Medical University in Szczecin, Powstancow Wlkp. 72 Av., 70-111 Szczecin, Poland; [email protected] 3 Department of Pharmaceutical Chemistry, Pomeranian Medical University in Szczecin, Powstancow Wlkp. 72 Av., 70-111 Szczecin, Poland; [email protected] * Correspondence: [email protected] Abstract: Recent studies on cyclin-dependent kinase (CDK) inhibitors have revealed that small molecule drugs have become very attractive for the treatment of cancer and neurodegenerative disorders. Most CDK inhibitors have been developed to target the ATP binding pocket. However, CDK kinases possess a very similar catalytic domain and three-dimensional structure. These features make it difficult to achieve required selectivity. Therefore, inhibitors which bind outside the ATP binding site present a great interest in the biomedical field, both from the fundamental point of view and for the wide range of their potential applications. This review tries to explain whether the ATP competitive inhibitors are still an option for future research, and highlights alternative approaches to discover more selective and potent small molecule inhibitors. Keywords: cyclin-dependent kinase inhibitors; cancer; cell cycle; CDKs; CDK inhibitors Citation: Łukasik, P.; Baranowska-Bosiacka, I.; Kulczycka, K.; Gutowska, I. Inhibitors of Cyclin-Dependent Kinases: Types 1. Cyclin-Dependent Kinases (CDKs) and Their Mechanism of Action.
    [Show full text]
  • Inhibition of CDK4/6 As Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
    cancers Review Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives Alessandra Dall’Acqua 1,†, Michele Bartoletti 2,3,† , Nastaran Masoudi-Khoram 1,‡, Roberto Sorio 2, Fabio Puglisi 2,3 , Barbara Belletti 1 and Gustavo Baldassarre 1,* 1 Molecular Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, 33081 Aviano, Italy; [email protected] (A.D.); [email protected] (N.M.-K.); [email protected] (B.B.) 2 Medical Oncology and Cancer Prevention Molecular Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, 33081 Aviano, Italy; [email protected] (M.B.); [email protected] (R.S.); [email protected] (F.P.) 3 Department of Medicine (DAME), University of Udine, 33100 Udine, Italy * Correspondence: [email protected]; Tel.: +39-0434-659779; Fax: +39-0434-659429 † These authors equally contributed to the work. ‡ Present address: Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Simple Summary: Altered regulation of the cell cycle is a hallmark of cancer. The recent clinical success of the inhibitors of CDK4 and CDK6 has convincingly demonstrated that targeting cell cycle components may represent an effective anti-cancer strategy, at least in some cancer types. However, possible applications of CDK4/6 inhibitors in patients with ovarian cancer is still under evaluation. Citation: Dall’Acqua, A.; Bartoletti, M.; Masoudi-Khoram, N.; Sorio, R.; Here, we describe the possible biological role of CDK4 and CDK6 complexes in ovarian cancer and Puglisi, F.; Belletti, B.; Baldassarre, G. provide the rationale for the use of CDK4/6 inhibitors in this pathology, alone or in combination Inhibition of CDK4/6 as Therapeutic with other drugs.
    [Show full text]